This Will be a Randomized Comparison of the Proteomic Effects of Vicadrostat/Empagliflozin Versus Empagliflozin and Versus Empagliflozin/Spironolactone in Heart Failure Patients With Preserved Ejection Fraction

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 200 participants.

Also called NCT07857772

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07857772
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07857772. Randomized; quadruple masking; primary purpose treatment. Start 2027-03 (anticipated); primary completion 2028-05 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
This Will be a Randomized Comparison of the Proteomic Effects of Vicadrostat/Empagliflozin Versus Empagliflozin and Versus Empagliflozin/Spironolactone in Heart Failure Patients With Preserved Ejection Fraction
Acronym
SPECTRA-HFpEF
Intervention (Drug)
empa plus vica
Intervention (Drug)
Comparator: empa 10 plus spironolactone
Lead sponsor
Baim Institute for Clinical Research (class: other)

Record details

Record id
cardio:ct-nct07857772
Content hash
f58aa3fc57a28d1185af7237c95d7bb1a809dad228eaeb7516eb93a462ac4166